Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | — | $1.19M | $164M | $264M |
| Revenue growth | — | — | — | — | — | — | — | — | 13699.0% | 60.6% |
| Operating income | -$53.6M | -$92.9M | -$128M | -$207M | -$262M | -$343M | -$399M | -$461M | -$395M | -$403M |
| Operating margin | — | — | — | — | — | — | — | -38735.0% | -240.9% | -153.1% |
| Net income | -$52.9M | -$92.1M | -$124M | -$198M | -$260M | -$342M | -$396M | -$444M | -$372M | -$391M |
| Net margin | — | — | — | — | — | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (diluted) | -$1.85 | -$1.41 | -$1.27 | -$1.59 | -$1.88 | -$2.23 | -$2.49 | -$1.89 | -$1.28 | -$1.09 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.7M | -$78.7M | -$101M | -$159M | -$205M | -$228M | -$293M | -$362M | -$353M | -$302M |
| Capital expenditures | $1.52M | $1.03M | $1.20M | $6.92M | $46.8M | $37.6M | $20.4M | $22.3M | $11.1M | $33.8M |
| Free cash flow | -$34.2M | -$79.7M | -$102M | -$166M | -$252M | -$266M | -$313M | -$384M | -$364M | -$336M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $107M | $145M | $82.2M | $14.0M | $67.3M | $78.2M | $232M | $115M | $116M | $163M |
| Total assets | $172M | $155M | $481M | $345M | $768M | $777M | $664M | $780M | $910M | $913M |
| Total liabilities | — | $9.89M | $14.6M | $45.7M | $112M | $156M | $164M | $196M | $200M | $215M |
| Shareholders' equity | $167M | $145M | $466M | $299M | $656M | $622M | $500M | $585M | $710M | $699M |
| Retained earnings | -$157M | -$249M | -$373M | -$571M | -$830M | -$1.17B | -$1.57B | -$2.01B | -$2.38B | -$2.78B |
| Shares (wtd avg diluted) | 62.2M | 73.2M | 123M | 124K | 138K | 153K | 159K | 235K | 290K | 357K |
Every figure is extracted from IOVANCE BIOTHERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.